Istituto di Candiolo, IRCCS

Candiolo 10060

2 studies enrolling now · 7 studies all time

What they study most

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Central Nervous System Neoplasms, HER2-Positive Primary Breast Cancer, Head and Neck Cancer, Metastatic Non Small Cell Lung Cancer, Neoplasms, Neoplasms by Site, Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer — Recruiting now
• Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer — Recruiting now
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer — Running, not enrolling
• The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC — Completed
• A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) — Stopped early